We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
OptiNose Inc | NASDAQ:OPTN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.02 | -1.85% | 1.06 | 1.05 | 1.06 | 1.08 | 1.05 | 1.05 | 65,487 | 19:08:58 |
By Colin Kellaher
Shares of Optinose plunge in premarket trading Wednesday after the pharmaceutical company said the U.S. Food and Drug Administration has extended the review of a request for expanded approval of its Xhance nasal spray by three months.
Optinose, which is seeking approval of Xhance as a treatment for chronic rhinosinusitis, said the FDA needs more time to review additional efficacy subset analyses the Yardley, Pa., company recently submitted at the agency's request.
Optinose said the FDA extended its target action date on the application to March 16, 2024.
Optinose shares, which closed Tuesday at $1.47, were recently down 22% to $1.14 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 06, 2023 08:33 ET (13:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year OptiNose Chart |
1 Month OptiNose Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions